- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Zydus Lifesciences wins USFDA approval for Lubiprostone Capsules to treat constipation
The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, India.
Ahmedabad: Zydus Lifesciences Limited has announced that the company has received final approval for Lubiprostone Capsules, 8 mcg and 24 mcg (USRLD: Amitiza Capsules) from the United States Food and Drug Administration (USFDA).Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation). The drug...
Ahmedabad: Zydus Lifesciences Limited has announced that the company has received final approval for Lubiprostone Capsules, 8 mcg and 24 mcg (USRLD: Amitiza Capsules) from the United States Food and Drug Administration (USFDA).
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation).
The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Lubiprostone Capsules, 8 mcg and 24 mcg had annual sales of USD 196.5 mn in the United States (IQVIA MAT, January 2023). The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences Depression drug Doxepin Hydrochloride bags USFDA okay
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751